Compare · ORKA vs VNRX
ORKA vs VNRX
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and VolitionRX Limited (VNRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and VNRX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $3.63B, about 234.9x VNRX ($15.4M).
- Over the past year, ORKA is up 409.4% and VNRX is down 87.4% - ORKA leads by 496.8 points.
- ORKA has been more active in the news (11 items in the past 4 weeks vs 6 for VNRX).
- ORKA has more recent analyst coverage (11 ratings vs 4 for VNRX).
PerformanceORKA+409.39%VNRX-87.43%
2025-06-09+0.00%2026-06-08
- Company
- Oruka Therapeutics Inc.
- VolitionRX Limited
- Price
- $64.03+6.51%
- $1.39-22.63%
- Market cap
- $3.63B
- $15.4M
- 1M return
- +0.02%
- -42.29%
- 1Y return
- +409.39%
- -87.43%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- AMEX
- IPO
- 2015
- News (4w)
- 11
- 6
- Recent ratings
- 11
- 4
VNRX
VolitionRX Limited
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.
Latest ORKA
- Oruka Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Dambkowski Carl
- SEC Form 4 filed by Director Kulkarni Samarth
- SEC Form 4 filed by Director Martin Christopher Nathan
- SEC Form 4 filed by Director Ball Kristine M
- SEC Form 4 filed by Director Fairmount Funds Management Llc
- Oruka Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation
- Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
- Director Dambkowski Carl exercised 62,260 shares at a strike of $7.95 and sold $6,191,366 worth of shares (105,000 units at $58.97) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 73,743 units (SEC Form 4)
Latest VNRX
- VolitionRx Announces Pricing of $4.6 Million Public Offering
- SEC Form 424B5 filed by VolitionRX Limited
- VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
- SEC Form DEF 14A filed by VolitionRX Limited
- VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
- VolitionRX Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement
- VolitionRX Limited filed SEC Form 8-K: Leadership Update
- Amendment: SEC Form SCHEDULE 13G/A filed by VolitionRX Limited
- SEC Form 10-Q filed by VolitionRX Limited
- VolitionRX Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits